Deutsche Bank Aktiengesellschaft Lowers Indivior (LON:INDV) Price Target to GBX 1,500

Indivior (LON:INDVGet Free Report) had its target price decreased by Deutsche Bank Aktiengesellschaft from GBX 2,350 ($30.10) to GBX 1,500 ($19.21) in a report released on Tuesday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 92.31% from the company’s current price.

Indivior Trading Up 3.1 %

Shares of LON:INDV opened at GBX 780 ($9.99) on Tuesday. The company has a 50 day moving average of GBX 1,310.67 and a 200-day moving average of GBX 1,415.90. The firm has a market cap of £1.05 billion, a P/E ratio of 26,000.00, a P/E/G ratio of -5.57 and a beta of 0.06. Indivior has a twelve month low of GBX 653 ($8.36) and a twelve month high of GBX 1,938 ($24.82). The company has a current ratio of 0.93, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00.

Indivior Company Profile

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Further Reading

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.